Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Dillon

Showing results (161-170 of 176) with videos related to

Pageof 18
Sort By:
Alimentary Pharmacology & Therapeutics|December 6, 2021
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approachJeffrey V Lazarus, Henry E Mark, Massimo Colombo, et al.
The Lancet. Gastroenterology & Hepatology|July 1, 2026
The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology CommissionHelen Jarvis, Paul N Brennan, Teresa Casanovas, et al.
Annals of the New York Academy of Sciences|September 29, 2011
Barrett's esophagus: proton pump inhibitors and chemoprevention IGeorge Triadafilopoulos, Antonio Taddei, Paolo Bechi, et al.
Trials|September 27, 2022
ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis-study protocol for an interventional randomised controlled trialDominic Crocombe, Norin Ahmed, Indran Balakrishnan, et al.
Plos One|June 23, 2012
Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variantColin N A Palmer, Cristina Maglio, Carlo Pirazzi, et al.
Nature Medicine|January 10, 2025
Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trialPaul N Brennan, Mark MacMillan, Thomas Manship, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 11, 2012
The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up callRichard S Tedder, Alison J Rodger, Lori Fries, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
The Lancet Regional Health. Europe|June 10, 2026
Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver diseaseNicola Pugliese, Trenton M White, Paul N Brennan, et al.
Pageof 18

Showing results (161-170 of 176) with videos related to

Sort By:
Pageof 18
Alimentary Pharmacology & Therapeutics|December 6, 2021
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approachJeffrey V Lazarus, Henry E Mark, Massimo Colombo, et al.
The Lancet. Gastroenterology & Hepatology|July 1, 2026
The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology CommissionHelen Jarvis, Paul N Brennan, Teresa Casanovas, et al.
Annals of the New York Academy of Sciences|September 29, 2011
Barrett's esophagus: proton pump inhibitors and chemoprevention IGeorge Triadafilopoulos, Antonio Taddei, Paolo Bechi, et al.
Trials|September 27, 2022
ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis-study protocol for an interventional randomised controlled trialDominic Crocombe, Norin Ahmed, Indran Balakrishnan, et al.
Plos One|June 23, 2012
Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variantColin N A Palmer, Cristina Maglio, Carlo Pirazzi, et al.
Nature Medicine|January 10, 2025
Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trialPaul N Brennan, Mark MacMillan, Thomas Manship, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 11, 2012
The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up callRichard S Tedder, Alison J Rodger, Lori Fries, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
The Lancet Regional Health. Europe|June 10, 2026
Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver diseaseNicola Pugliese, Trenton M White, Paul N Brennan, et al.
Pageof 18